Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions

Karnes, J.H., Miller, M.A., White, K.D., Konvinse, K.C., Pavlos, R.K., Redwood, A.J., Peter, J.G., Lehloenya, R., Mallal, S.A. and Phillips, E.J. (2019) Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology, 59 (1). pp. 463-486.

Abstract

Adverse drug reactions (ADRs) are a significant health care burden. Immunemediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen (HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.

Item Type:	Journal Article
Murdoch Affiliation:	Institute for Immunology and Infectious Diseases
Publisher:	Annual Reviews
Copyright:	© 2019 by Annual Reviews
URI:	http://researchrepository.murdoch.edu.au/id/eprint/43415

Item Control Page